CliffBio
biologic

Shingrix

Zoster Vaccine Recombinant, Adjuvanted

Loss of exclusivityOctober 2029projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameShingrix
Active ingredientZoster Vaccine Recombinant, Adjuvanted
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2017
Marketing statusRx

More from GlaxoSmithKline Biologicals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Shingrix patent cliff — loss of exclusivity October 2029 | CliffBio